Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
Julphar
Cantor Fitzgerald
Federal Trade Commission
AstraZeneca
Farmers Insurance
Fuji
Johnson and Johnson

Generated: December 10, 2018

DrugPatentWatch Database Preview

Litigation Details for SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)

« Back to Dashboard

SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)

Small Molecule Drugs cited in SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-07-10 11 HOLDER or l'ATENT OR TRADEMARK. I us 9,393,237 7/19/2016 … ~ 0 Trademarks or ~Patents. ( O the patent action involves 35 U.S.C. § 292.): DOCKET… AO120 Patent Form filed. (jr) (Entered: 07/10/2017) 10 July 2017 PACER Document … REPORT ON THE Director of the U.S. Patent and Trademark Office … ACTION REGARDING A PATENT OR Alexandria, VA 22313 External link to document
2017-07-20 22 in US-A-3,454,554. Reboxetine can be prepared as described in U.S. Patent Publication…issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration…infringes Plaintiff’s U.S. Patent Nos. 5,874,447 (“’447 patent”); 7,598,271 (“’271 patent”); 8,658,663…,663 (“’663 patent”); and 8,946,251 (“’251 patent”) (collectively “patents-in-suit”) under 35…infringes Plaintiff’s U.S. Patent Nos. 5,874,447 (“’447 patent”); 7,598,271 (“’271 patent”); 8,658,663 External link to document
2017-10-20 60 . Patent Nos. 5,874,447 2 on the evidence presented…this Court: U.S. Patent Nos. 8,658,663 (the “‘663 patent”) and 8,946,251 (the “‘251 patent”). All three …237 patent is identical to those of the ‘663 and ‘251 patents. The ‘663 and ‘251 patents are… the ‘237 patent is very similar to claim I of the ‘251 patent. Claim 1 of the ‘251 patent recites: …would infringe the claims of U.S. Patent No. 9,393,237 (the “‘237 patent”),’ For the reasons set forth below External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chubb
UBS
Baxter
QuintilesIMS
Colorcon
Accenture
Merck
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.